Navigation Links
Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection
Date:5/30/2013

SOUTH SAN FRANCISCO, CA May 30, 2013 Alios BioPharma, Inc. today announced that it has begun oral dosing of ALS-8176 in a Phase 1 clinical trial. ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside analog that is being developed for the treatment of acute RSV infection. It is the only known nucleoside analog currently in clinical development for the treatment of RSV. ALS-8176 demonstrates potent anti-viral activity across multiple strains of RSV in preclinical studies and represents an important step forward in the development of more effective treatments for this serious and often life threatening disease.

The randomized, double-blind, placebo-controlled, Phase 1 study of orally administered ALS-8176 will evaluate safety, tolerability, and pharmacokinetics of single ascending doses and multiple ascending doses in healthy volunteers. The trial will assess several dose levels in up to 90 healthy adults.

ALS-8176 was discovered following the optimization of screening hits obtained through testing the Alios proprietary nucleoside analog library against replicating RSV in cell culture. The compound acts by blocking replication through a classic chain-termination mechanism and inhibits all RSV strains tested.

Due to their high barrier to viral resistance, nucleoside analogs have become the backbone of antiviral therapy in many clinical settings including the treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV) and herpes simplex virus (HSV). More recently, emerging data suggest the pivotal role nucleoside analogs will play in the future treatment of chronic hepatitis C (HCV).

"Alios believes ALS-8176 has great potential to become an effective first-line antiviral therapy for RSV infection, a disease where few treatment options currently exist," said Lawrence M. Blatt, PhD, Chief Executive Officer. "The advancement of ALS-8176 for RSV, together with the recently repo
'/>"/>

Contact: John Donovan
press@aliosbiopharma.com
650-635-5504
Alios BioPharma, Inc.
Source:Eurekalert

Page: 1 2

Related biology news :

1. Exclusive agreement to distribute Affinity Biosensors Archimedes system extends Malvern Instruments biopharma solutions
2. Discovery of a molecule that initiates maturation of mammalian eggs can lead to more IVF pregnancies
3. Carnegie Mellon neuroscientists discover new phase of synaptic development
4. Monoclonal Antibody with Xencors High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
5. FDA approves Phase II of stem cell trial for ALS led by U-Ms Dr. Eva Feldman
6. In beef production, cow-calf phase contributes most greenhouse gases
7. F1000Research, the first Open Science publisher, launches following a successful beta testing phase
8. National Geographic unveils new phase of genographic project
9. King Richard III search in new phase after discovery has potential to rewrite history
10. Center for Clinical and Translational Science awards new pilot grants
11. Elseviers Maturitas publishes clinical guide on endometrial assessment in postmenopausal women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2015)... , April 13, 2015  higi, a leading cloud-based ... to more fully engage with their communities around health ... privacy protected and secure API.  ... the most accessible, affordable, and convenient vehicle to receive ... The API will allow higi,s ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
(Date:4/2/2015)... , April 2, 2015 At its 2015 ... Lake City , the American College of Medical ... new directors to its Board.  Members of the ACMG ... and for forming and advancing its policies and programs. ... profession. "It,s an eventful time in medical ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... University, in London, Canada, have developed a CT (Computed Tomography) ... Battista, Chair of the Department of Medical Biophysics at the ... the London Regional Cancer Program at London Health Sciences Centre ... interactive way to teach CT imaging techniques to a wide ...
... Research Institute (OHRI) and the University of Ottawa (uOttawa) has ... (CIHR) and $75,000 from the Stem Cell Network to lead ... cell therapy for septic shock. This deadly condition occurs when ... system, resulting in severe organ damage and death in 30 ...
... Epigenetics is the new hip science. Time Magazine,s front cover ... explains why. Its more explicit subtitle provided the hook - ,The ... change your genes - and those of your kids,. Who ... ways in which the genetic code in our DNA is regulated ...
Cached Biology News:Mini-CT scanner developed as a teaching tool 2Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock 2Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock 3Epigenetics and epidemiology -- hip, hype and science 2Epigenetics and epidemiology -- hip, hype and science 3
(Date:5/5/2015)... 05, 2015 VetStem Biopharma, proudly ... Health, Jeffrey Schaffer, DVM, as Director of Veterinary ... years of experience in the veterinary regenerative medicine ... to our veterinarian lead organization”. Dr. Alexis ... Schaffer will be responsible for all technical activities ...
(Date:5/5/2015)... 5, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... continue trading on OTCQB  Marketplace, the market for ... allows for a continuous public market for trading ... real-time quotes and market information on us through ... Marketplace includes U.S. and international companies in venture ...
(Date:5/5/2015)... NEW YORK , May 5, 2015 /PRNewswire/ ... today announced that Andrew Gengos , President and ... on May 7, 2015. DATE:  Thursday, May ... LINK:  http://VirtualInvestorConferences.com > click the ... will be a live, interactive online event where ...
(Date:5/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/x5gjj3/clinical ... "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services ... Global Version" report to their offering. ... of molecular diagnostics and pharmacogenics hold the promise ... that is moving out of the national and ...
Breaking Biology Technology:Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7 2Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2
... BEIJING, Aug. 14 /PRNewswire-Asia-FirstCall/ -- Lotus ... growing developer and,producer of prescription drugs and licensed national seller ... financial results,for the quarter and six months ended June 30, ... Highlights and Developments:, -- Q2 diluted EPS ...
... HARBIN, China, Aug. 14 /PRNewswire-Asia-FirstCall/ -- ... Company") (Nasdaq: CSKI ), a,leading fully integrated pharmaceutical ... financial results for the second quarter,of 2009. , , ... Total revenues increased 35.5% year-over-year to $32.2 million, ...
... ... for ISP,s Vincience™ Biofunctional Ingredients, Rapidly and Effectively , ... (PRWEB) August 14, 2009 -- ... global supplier of advanced personal care ingredients, announced that they have formed an ...
Cached Biology Technology:Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results 2Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results 3Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results 4Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results 5Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results 6Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results 7Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results 8Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results 9Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results 10Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results 11China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 2China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 3China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 4China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 5China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 6China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 7China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 8China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 9China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 10China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 11Cellworks Group and ISP Personal Care Collaborate to Demonstrate Effectiveness of Proteomics-Based Computer Modeling of Skin Biology 2Cellworks Group and ISP Personal Care Collaborate to Demonstrate Effectiveness of Proteomics-Based Computer Modeling of Skin Biology 3Cellworks Group and ISP Personal Care Collaborate to Demonstrate Effectiveness of Proteomics-Based Computer Modeling of Skin Biology 4
anti-Lactate Dehydrogenase...
6-keto Prostaglandin F1α EIA Antiserum 6-keto-PGF1alpha EIAs prostaglandins antisera enzyme immunoassays reagents 6-keto-PGF1.alpha....
... developed for use with immunohistochemical (IHC) ... background staining due to endogenous peroxidase. ... with hydrogen peroxide. This reagent ... additional novel components to further quench ...
Phospho-Btk (Tyr223) Antibody...
Biology Products: